Under the UK Patient Group Directions for Wegovy and Mounjaro , continued treatment for weight management is only permitted while: BMI remains at or above 22 kg/m This applies: To maintenance treatment To all ethnicities Regardless of dose strength Once BMI falls below 22 kg/m , GLP-1 medication must usually be stopped
These formulations have not undergone FDA clinical trials to evaluate their safety, efficacy, or therapeutic equivalence to any FDA-approved medications
That mindset, she warns, can overshadow the critical role of diet, exercise, and lifestyle support in achieving sustainable health
Most patients experience noticeable effects from Zepbound quickly
Local Holladay clinic says more Utah patients are seeking doctor-guided GLP-1 weight-loss treatments like semaglutide this holiday season, with screening, labs and ongoing monitoring
Whether the superior effects of semaglutide and dulaglutide on stroke reduction compared to other GLP-1RAs arise from inherent differences in drug properties or disparities in trial design remains uncertain